Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries’ specialty product Ilumetri has been included in category B of China's national reimbursement drug list. Ilumetri is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The inclusion of Ilumetri (Tildrakizumab) in China's national reimbursement drug list will be officially implemented from January 1, 2024. 

In June 2019, Sun Pharma had out-licensed Tildrakizumab to a subsidiary of China Medical System Holdings (CMS), for the Greater China market. Ilumetri was approved for marketing in China in May 2023. 

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.